IBD patients have been found to have a higher risk of lymphoma.

Published Date: 26 Apr 2023

According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.

Read Full News

Latest News

Older Adults Have Worse Lower GI Bleeding Outcomes

Older adults with lower gastrointestinal bleeding present with more severe disease and substantially higher 30-day mortality—yet most deaths stem not from bleeding itself, but from decompensation of underlying chronic conditions.

Vaccine to Prevent Pancreatic Cancer Shows Early Promise

The vaccine spurs a lasting immune response in people at a high risk for pancreatic cancer. Whether it staves off the disease remains to be seen.

Durvalumab Tied to Extended Biliary Tract Cancer OS Benefit

Researchers examine 4-year outcomes of the phase 3 TOPAZ-1 study.

Low-Volume PEG Wins for Inpatient Bowel Cleansing

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Why the Painless Abdominal Bloating in Middle-Age Man?

Admitted for pyelonephritis, but his diagnostic journey is just beginning

Beware Aspiration Risk in Chronic Pot Users

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Latest News

Older adults with lower gastrointestinal bleeding present with more severe disease and substantially higher 30-day mortality—yet most deaths stem not from bleeding itself, but from decompensation of underlying chronic conditions.

The vaccine spurs a lasting immune response in people at a high risk for pancreatic cancer. Whether it staves off the disease remains to be seen.

Researchers examine 4-year outcomes of the phase 3 TOPAZ-1 study.

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Admitted for pyelonephritis, but his diagnostic journey is just beginning

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

News All Time

Perfusion Preservation Strategy Boosts Liver Transplant Outcomes

Portal-venous hypothermic oxygenated perfusion reduced incidence of early allograft dysfunction

GLP-1s and Chronic Pancreatitis; Hypoglycemia After Bowel Prep; Lower GI Bleeding

News and commentary from the world of gastroenterology and hepatology

Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials

Findings "will change the landscape" of treatment, researcher says

TIPS Was Tops for Refractory Hydrothorax in Cirrhosis

Majority of patients who received TIPS had a complete clinical response

Enhanced MRI Tops Ultrasound in Catching Early Liver Cancer

MRI approach also led to fewer false referrals

Multicancer Early Detection Test Fails to Reduce Cancers Detected at Late Stages

However, an increase in the detection of stage I/II cancers was observed

'A Grand Slam' in Pancreatic Cancer: Novel Pill Doubles Survival

RASolute 302 findings herald a new standard of care in previously treated patients

Albumin 5% Cut Mortality Rates in Sudden Liver Failure With Other Organ Failure

Treatment may be an effective bridge to transplantation for acute-on-chronic liver failure

Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis

More than half of patients saw a biochemical response by 1 year with the novel oral agent

Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival

Non-Operative Treatment for CRC May Include Observation After Complete Response

No difference in disease-free, overall survival compared with 3 years of maintenance therapy

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" expert asks
HTTP error: 503HTTP error: 503HTTP error: 503

Study Warns on Sugary Drinks and Liver Cancer

However, no association between artificially sweetened drinks and liver cancer observed

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot